GFP
CRSP icon

Gryphon Financial Partners’s CRISPR Therapeutics CRSP Stock Holding History

Gryphon Financial Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-95
Closed -$6K – 300
2018
Q2 		$6K Buy
95
+20
+27% +$1.14K ﹤0.01% 616
2018
Q1 		$3K Buy
75
+25
+50% +$1.03K ﹤0.01% 772
2017
Q4 		$1K Buy
+50
New +$950 ﹤0.01% 949

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Gryphon Financial Partners's CRSP Position: Q3 2018 in Review

Gryphon Financial Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 95 shares — an estimated $6K sold.

Gryphon Financial Partners first reported a position in CRSP in Q4 2017 and held it in 3 quarters. The position peaked at $6K in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Gryphon Financial Partners reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 95 CRISPR Therapeutics shares in Q3 2018, an estimated $6K.
  • Gryphon Financial Partners first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's CRISPR Therapeutics position peaked at $6K in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.